NeoGenomics said on Monday that it will work with Eli Lilly on a program designed to provide no-cost genomic testing to patients with metastatic non-small cell lung cancer (NSCLC).
Through the partnership, NSCLC patients eligible for the Lilly Lung Cancer Sponsored Testing Program will be tested using NeoGenomics’ NeoType DNA and RNA Assay, a next-generation sequencing-based panel designed to detect genomic alterations in NSCLC that can guide targeted therapy decisions or identify clinical trial opportunities for patients.
In cases where NeoType results are not obtainable due to low tissue input or when an invasive biopsy is medically contraindicated, eligible patients may be tested with NeoGenomics’ InVisionFirst Lung Liquid Biopsy.
Financial and other terms of the partnership were not disclosed.
“This collaboration has great potential to drive awareness of critical biomarker testing, while at the same time improving access to testing for patients who may be eligible for unique targeted therapies,” Derek Lyle, chief medical officer at Fort Myers, Florida-based NeoGenomics, said in a statement.
Indianapolis-based Eli Lilly is developing a number of targeted therapies for NSCLC including the RET inhibitor Retsevmo (selpercatinib), the PD-1 inhibitor Tyvyt (sintilimab), and the KRAS G12C inhibitor LY3537982.
In mid-2020, Eli Lilly partnered with NeoGenomics on a molecular testing program for thyroid cancer patients.
This article originally appeared on GenomeWeb. Click here for more information.
